{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T16:10:17Z","timestamp":1794067817583,"version":"4.8.0"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2021,2,24]],"date-time":"2021-02-24T00:00:00Z","timestamp":1614124800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,2,24]],"date-time":"2021-02-24T00:00:00Z","timestamp":1614124800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000265","name":"RCUK | Medical Research Council","doi-asserted-by":"publisher","award":["MR\/ K012665"],"award-info":[{"award-number":["MR\/ K012665"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001349","name":"MOH | National Medical Research Council","doi-asserted-by":"publisher","award":["MR\/S001697\/1"],"award-info":[{"award-number":["MR\/S001697\/1"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000268","name":"RCUK | Biotechnology and Biological Sciences Research Council","doi-asserted-by":"publisher","award":["BB\/M011151\/1"],"award-info":[{"award-number":["BB\/M011151\/1"]}],"id":[{"id":"10.13039\/501100000268","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009187","name":"RCUK | MRC | Medical Research Foundation","doi-asserted-by":"publisher","award":["MR\/S001697\/1"],"award-info":[{"award-number":["MR\/S001697\/1"]}],"id":[{"id":"10.13039\/501100009187","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2021,3,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Protein ubiquitination is a critical regulator of cellular homeostasis. Aberrations in the addition or removal of ubiquitin can result in the development of cancer and key components of the ubiquitination machinery serve as oncogenes or tumour suppressors. An emerging target in the development of cancer therapeutics are the deubiquitinase (DUB) enzymes that remove ubiquitin from protein substrates. Whether this class of enzyme plays a role in cervical cancer has not been fully explored. By interrogating the cervical cancer data from the TCGA consortium, we noted that the DUB USP13 is amplified in ~15% of cervical cancer cases. We confirmed that USP13 expression was increased in cervical cancer cell lines, cytology samples from patients with cervical disease and in cervical cancer tissue. Depletion of USP13 inhibited cervical cancer cell proliferation. Mechanistically, USP13 bound to, deubiquitinated and stabilised Mcl-1, a pivotal member of the anti-apoptotic BCL-2 family. Furthermore, reduced Mcl-1 expression partially contributed to the observed proliferative defect in USP13 depleted cells. Importantly, the expression of USP13 and Mcl-1 proteins correlated in cervical cancer tissue. Finally, we demonstrated that depletion of USP13 expression or inhibition of USP13 enzymatic activity increased the sensitivity of cervical cancer cells to the BH3 mimetic inhibitor ABT-263. Together, our data demonstrates that USP13 is a potential oncogene in cervical cancer that functions to stabilise the pro-survival protein Mcl-1, offering a potential therapeutic target for these cancers.<\/jats:p>","DOI":"10.1038\/s41388-021-01679-8","type":"journal-article","created":{"date-parts":[[2021,2,24]],"date-time":"2021-02-24T02:04:38Z","timestamp":1614132278000},"page":"2112-2129","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":59,"title":["The deubiquitinase (DUB) USP13 promotes Mcl-1 stabilisation in cervical cancer"],"prefix":"10.1038","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6487-5450","authenticated-orcid":false,"given":"Ethan L.","family":"Morgan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Molly R.","family":"Patterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Barba-Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"Scarth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5978-4693","authenticated-orcid":false,"given":"Andrew","family":"Macdonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,24]]},"reference":[{"key":"1679_CR1","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.cell.2010.11.012","volume":"143","author":"MJ Clague","year":"2010","unstructured":"Clague MJ, Urb\u00e9 S. Ubiquitin: same molecule, different degradation pathways. Cell. 2010;143:682\u20135.","journal-title":"Cell."},{"key":"1679_CR2","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/cr.2016.39","volume":"26","author":"KN Swatek","year":"2016","unstructured":"Swatek KN, Komander D. Ubiquitin modifications. Cell Res. 2016;26:399\u2013422.","journal-title":"Cell Res."},{"key":"1679_CR3","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1242\/jcs.183954","volume":"129","author":"M Akutsu","year":"2016","unstructured":"Akutsu M, Dikic I, Bremm A. Ubiquitin chain diversity at a glance. J Cell Sci. 2016;129:875\u201380.","journal-title":"J Cell Sci"},{"key":"1679_CR4","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1038\/cr.2016.31","volume":"26","author":"X Huang","year":"2016","unstructured":"Huang X, Dixit VM. Drugging the undruggables: exploring the ubiquitin system for drug development. Cell Res 2016;26:484\u201398.","journal-title":"Cell Res"},{"key":"1679_CR5","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1038\/nrm2731","volume":"10","author":"D Komander","year":"2009","unstructured":"Komander D, Clague MJ, Urb\u00e9 S. Breaking the chains: structure and function of the deubiquitinases. Nat Rev Mol Cell Biol. 2009;10:550\u201363.","journal-title":"Nat Rev Mol Cell Biol."},{"key":"1679_CR6","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1074\/jbc.M604711200","volume":"282","author":"HAJ Alwan","year":"2007","unstructured":"Alwan HAJ, Leeuwen JEM. van. UBPY-mediated epidermal growth factor receptor (EGFR) de-ubiquitination promotes EGFR degradation. J Biol Chem. 2007;282:1658\u201369.","journal-title":"J Biol Chem."},{"key":"1679_CR7","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.cell.2009.12.032","volume":"140","author":"J Yuan","year":"2010","unstructured":"Yuan J, Luo K, Zhang L, Cheville JC, Lou Z. USP10 regulates p53 localization and stability by deubiquitinating p53. Cell. 2010;140:384\u201396.","journal-title":"Cell."},{"key":"1679_CR8","doi-asserted-by":"publisher","first-page":"3734","DOI":"10.1073\/pnas.1411713112","volume":"112","author":"X-X Sun","year":"2015","unstructured":"Sun X-X, He X, Yin L, Komada M, Sears RC, Dai M-S. The nucleolar ubiquitin-specific protease USP36 deubiquitinates and stabilizes c-Myc. Proc Natl Acad Sci USA. 2015;112:3734\u20139.","journal-title":"Proc Natl Acad Sci USA."},{"key":"1679_CR9","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1038\/s41467-019-08481-x","volume":"10","author":"MK Park","year":"2019","unstructured":"Park MK, Yao Y, Xia W, Setijono SR, Kim JH, Vila IK, et al. PTEN self-regulates through USP11 via the PI3K-FOXO pathway to stabilize tumor suppression. Nat Commun. 2019;10:636\u201317.","journal-title":"Nat Commun."},{"key":"1679_CR10","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/S1097-2765(04)00157-1","volume":"13","author":"M Li","year":"2004","unstructured":"Li M, Brooks CL, Kon N, Gu W. A dynamic role of HAUSP in the p53-Mdm2 pathway. Mol Cell 2004;13:879\u201386.","journal-title":"Mol Cell"},{"key":"1679_CR11","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/nature24451","volume":"550","author":"AP Turnbull","year":"2017","unstructured":"Turnbull AP, Ioannidis S, Krajewski WW, Pinto-Fernandez A, Heride C, Martin ACL, et al. Molecular basis of USP7 inhibition by selective small-molecule inhibitors. Nature. 2017;550:481\u20136.","journal-title":"Nature."},{"issue":"Sep","key":"1679_CR12","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/S0140-6736(13)60022-7","volume":"382","author":"EJ Crosbie","year":"2013","unstructured":"Crosbie EJ, Einstein MH, Franceschi S, Kitchener HC. Human papillomavirus and cervical cancer. Lancet (Lond, Engl) 2013;382(Sep):889\u201399.","journal-title":"Lancet (Lond, Engl)"},{"key":"1679_CR13","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1038\/nrc798","volume":"2","author":"H Hausen","year":"2002","unstructured":"Hausen H. zur. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer. 2002;2:342\u201350.","journal-title":"Nat Rev Cancer."},{"key":"1679_CR14","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1038\/nrc2886","volume":"10","author":"CA Moody","year":"2010","unstructured":"Moody CA, Laimins LA. Human papillomavirus oncoproteins: pathways to transformation. Nat Rev Cancer. 2010;10:550\u201360.","journal-title":"Nat Rev Cancer."},{"key":"1679_CR15","doi-asserted-by":"publisher","first-page":"27","DOI":"10.2217\/fvl.14.99","volume":"10","author":"M Mller","year":"2015","unstructured":"Mller M, Prescott EL, Wasson CW, Macdonald A. Human papillomavirus E5 oncoprotein: function and potential target for antiviral therapeutics. Future Virol. 2015;10:27\u201339.","journal-title":"Future Virol."},{"key":"1679_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1003237","volume":"9","author":"JM Spangle","year":"2013","unstructured":"Spangle JM, M\u00fcnger K. The HPV16 E6 oncoprotein causes prolonged receptor protein tyrosine kinase signaling and enhances internalization of phosphorylated receptor species. PLoS Pathog. 2013;9:e1003237.","journal-title":"PLoS Pathog"},{"key":"1679_CR17","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.15252\/emmm.201404976","volume":"7","author":"C He","year":"2015","unstructured":"He C, Mao D, Hua G, Lv X, Chen X, Angeletti PC, et al. The Hippo\/YAP pathway interacts with EGFR signaling and HPV oncoproteins to regulate cervical cancer progression. EMBO Mol Med. 2015;7:1426\u201349.","journal-title":"EMBO Mol Med"},{"key":"1679_CR18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1007835","volume":"15","author":"EL Morgan","year":"2019","unstructured":"Morgan EL, Macdonald A. Autocrine STAT3 activation in HPV positive cervical cancer through a virus-driven Rac1-NF\u03baB-IL-6 signalling axis. PLoS Pathog. 2019;15:e1007835.","journal-title":"PLoS Pathog"},{"key":"1679_CR19","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.3390\/cancers11121934","volume":"11","author":"EL Morgan","year":"2019","unstructured":"Morgan EL, Macdonald A. JAK2 inhibition impairs proliferation and sensitises cervical cancer cells to cisplatin-induced cell death. Cancers. 2019;11:1934.","journal-title":"Cancers."},{"key":"1679_CR20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1008624","volume":"16","author":"EL Morgan","year":"2020","unstructured":"Morgan EL, Patterson MR, Ryder EL, Lee SY, Wasson CW, Harper KL, et al. MicroRNA-18a targeting of the STK4\/MST1 tumour suppressor is necessary for transformation in HPV positive cervical cancer. PLoS Pathog. 2020;16:e1008624.","journal-title":"PLoS Pathog."},{"key":"1679_CR21","doi-asserted-by":"publisher","first-page":"4734","DOI":"10.3390\/v7082842","volume":"7","author":"JOM Bello","year":"2015","unstructured":"Bello JOM, Nieva LO, Paredes AC, Gonzalez AMF, Zavaleta LR, Lizano M. Regulation of the Wnt\/\u03b2-catenin signaling pathway by human papillomavirus E6 and E7 oncoproteins. Viruses. 2015;7:4734\u201355.","journal-title":"Viruses."},{"key":"1679_CR22","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/0092-8674(93)90384-3","volume":"75","author":"M Scheffner","year":"1993","unstructured":"Scheffner M, Huibregtse JM, Vierstra RD, Howley PM. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell. 1993;75:495\u2013505.","journal-title":"Cell."},{"key":"1679_CR23","first-page":"4620","volume":"56","author":"SN Boyer","year":"1996","unstructured":"Boyer SN, Wazer DE, Band V. E7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway. Cancer Res. 1996;56:4620\u20134.","journal-title":"Cancer Res"},{"key":"1679_CR24","doi-asserted-by":"publisher","first-page":"9737","DOI":"10.1128\/JVI.00881-07","volume":"81","author":"K Huh","year":"2007","unstructured":"Huh K, Zhou X, Hayakawa H, Cho J-Y, Libermann TA, Jin J, et al. Human papillomavirus type 16 E7 oncoprotein associates with the cullin 2 ubiquitin ligase complex, which contributes to degradation of the retinoblastoma tumor suppressor. J Virol. 2007;81:9737\u201347.","journal-title":"J Virol"},{"key":"1679_CR25","first-page":"27","volume":"7","author":"D Pim","year":"1992","unstructured":"Pim D, Collins M, Banks L. Human papillomavirus type 16 E5 gene stimulates the transforming activity of the epidermal growth factor receptor. Oncogene. 1992;7:27\u201332.","journal-title":"Oncogene."},{"key":"1679_CR26","doi-asserted-by":"publisher","first-page":"4521","DOI":"10.1128\/JVI.67.8.4521-4532.1993","volume":"67","author":"SW Straight","year":"1993","unstructured":"Straight SW, Hinkle PM, Jewers RJ, McCance DJ. The E5 oncoprotein of human papillomavirus type 16 transforms fibroblasts and effects the downregulation of the epidermal growth factor receptor in keratinocytes. J Virol. 1993;67:4521\u201332.","journal-title":"J Virol."},{"key":"1679_CR27","doi-asserted-by":"publisher","first-page":"103581","DOI":"10.18632\/oncotarget.21658","volume":"8","author":"CW Wasson","year":"2017","unstructured":"Wasson CW, Morgan EL, M\u00fcller M, Ross RL, Hartley M, Roberts S, et al. Human papillomavirus type 18 E5 oncogene supports cell cycle progression and impairs epithelial differentiation by modulating growth factor receptor signalling during the virus life cycle. Oncotarget. 2017;8:103581\u2013600.","journal-title":"Oncotarget."},{"key":"1679_CR28","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.antiviral.2018.08.005","volume":"158","author":"LF Wetherill","year":"2018","unstructured":"Wetherill LF, Wasson CW, Swinscoe G, Kealy D, Foster R, Griffin S, et al. Alkyl-imino sugars inhibit the pro-oncogenic ion channel function of human papillomavirus (HPV) E5. Antivir Res. 2018;158:113\u201321.","journal-title":"Antivir Res."},{"key":"1679_CR29","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1038\/sj.onc.1208453","volume":"24","author":"B Zhang","year":"2005","unstructured":"Zhang B, Srirangam A, Potter DA, Roman A. HPV16 E5 protein disrupts the c-Cbl-EGFR interaction and EGFR ubiquitination in human foreskin keratinocytes. Oncogene. 2005;24:2585\u20138.","journal-title":"Oncogene."},{"key":"1679_CR30","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.ccr.2008.10.007","volume":"14","author":"J An","year":"2008","unstructured":"An J, Mo D, Liu H, Veena MS, Srivatsan ES, Massoumi R, et al. Inactivation of the CYLD deubiquitinase by HPV E6 mediates hypoxia-induced NF-kappaB activation. Cancer Cell. 2008;14:394\u2013407.","journal-title":"Cancer Cell."},{"key":"1679_CR31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1003384","volume":"9","author":"R Karim","year":"2013","unstructured":"Karim R, Tummers B, Meyers C, Biryukov JL, Alam S, Backendorf C, et al. Human papillomavirus (HPV) upregulates the cellular deubiquitinase UCHL1 to suppress the keratinocyte\u2019s innate immune response. PLoS Pathog. 2013;9:e1003384.","journal-title":"PLoS Pathog"},{"key":"1679_CR32","doi-asserted-by":"publisher","first-page":"8545","DOI":"10.1128\/JVI.00379-14","volume":"88","author":"M Lehoux","year":"2014","unstructured":"Lehoux M, Gagnon D, Archambault J. E1-mediated recruitment of a UAF1-USP deubiquitinase complex facilitates human papillomavirus DNA replication. J Virol. 2014;88:8545\u201355.","journal-title":"J Virol."},{"key":"1679_CR33","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.molcel.2018.09.019","volume":"72","author":"S Kiran","year":"2018","unstructured":"Kiran S, Dar A, Singh SK, Lee KY, Dutta A. The deubiquitinase USP46 is essential for proliferation and tumor growth of HPV-transformed cancers. Mol Cell. 2018;72:823\u2013.e5.","journal-title":"Mol Cell."},{"key":"1679_CR34","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1038\/nature21386","volume":"543","author":"Network CGAR, Medicine AEC of, Services AB, Hospital BC, Medicine BC of, Hope BRI of C of, et al.","year":"2017","unstructured":"Network CGAR, Medicine AEC of, Services AB, Hospital BC, Medicine BC of, Hope BRI of C of, et al. Integrated genomic and molecular characterization of cervical cancer. Nature. 2017;543:378\u201384.","journal-title":"Nature."},{"key":"1679_CR35","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.celrep.2018.03.047","volume":"23","author":"Z Ge","year":"2018","unstructured":"Ge Z, Leighton JS, Wang Y, Peng X, Chen Z, Chen H, et al. Integrated genomic analysis of the ubiquitin pathway across cancer types. Cell Rep. 2018;23:213\u2013e3.","journal-title":"Cell Rep."},{"key":"1679_CR36","first-page":"1763","volume":"28","author":"N Bansal","year":"2008","unstructured":"Bansal N, Wright JD, Cohen CJ, Herzog TJ. Natural history of established low grade cervical intraepithelial (CIN 1) lesions. Anticancer Res. 2008;28:1763\u20136.","journal-title":"Anticancer Res."},{"key":"1679_CR37","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/S0006-291X(02)00360-1","volume":"293","author":"YW Chung","year":"2002","unstructured":"Chung YW, Jeong D, Won JY, Choi E-J, Choi YH, Kim IY. H(2)O(2)-induced AP-1 activation and its effect on p21(WAF1\/CIP1)-mediated G2\/M arrest in a p53-deficient human lung cancer cell. Biochemical biophysical Res Commun. 2002;293:1248\u201353.","journal-title":"Biochemical biophysical Res Commun"},{"key":"1679_CR38","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/sj.gene.6364455","volume":"9","author":"R Rio","year":"2008","unstructured":"Rio R, del, Noubade R, Subramanian M, Saligrama N, Diehl S, Rincon M, et al. SNPs upstream of the minimal promoter control IL-2 expression and are candidates for the autoimmune disease-susceptibility locus Aod2\/Idd3\/Eae3. Genes Immun. 2008;9:115\u201321.","journal-title":"Genes Immun."},{"key":"1679_CR39","doi-asserted-by":"publisher","first-page":"2760","DOI":"10.1002\/j.1460-2075.1996.tb00636.x","volume":"15","author":"S Gupta","year":"1996","unstructured":"Gupta S, Barrett T, Whitmarsh AJ, Cavanagh J, Sluss HK, D\u00e9rijard B, et al. Selective interaction of JNK protein kinase isoforms with transcription factors. EMBO J. 1996;15:2760\u201370.","journal-title":"EMBO J."},{"key":"1679_CR40","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1038\/ncomms1421","volume":"2","author":"X Zhao","year":"2011","unstructured":"Zhao X, Fiske B, Kawakami A, Li J, Fisher DE. Regulation of MITF stability by the USP13 deubiquitinase. Nat Commun. 2011;2:414\u20138.","journal-title":"Nat Commun."},{"key":"1679_CR41","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1038\/ncb2874","volume":"15","author":"J Zhang","year":"2013","unstructured":"Zhang J, Zhang P, Wei Y, Piao H-L, Wang W, Maddika S, et al. Deubiquitylation and stabilization of PTEN by USP13. Nat Cell Biol. 2013;15:1486\u201394.","journal-title":"Nat Cell Biol."},{"key":"1679_CR42","doi-asserted-by":"publisher","first-page":"13525","DOI":"10.1038\/ncomms13525","volume":"7","author":"C Han","year":"2016","unstructured":"Han C, Yang L, Choi HH, Baddour J, Achreja A, Liu Y, et al. Amplification of USP13 drives ovarian cancer metabolism. Nat Commun. 2016;7:13525\u201316.","journal-title":"Nat Commun."},{"key":"1679_CR43","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/s41467-017-02693-9","volume":"9","author":"S Zhang","year":"2018","unstructured":"Zhang S, Zhang M, Jing Y, Yin X, Ma P, Zhang Z, et al. Deubiquitinase USP13 dictates MCL1 stability and sensitivity to BH3 mimetic inhibitors. Nat Commun. 2018;9:215\u201312.","journal-title":"Nat Commun."},{"key":"1679_CR44","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1007\/s12032-011-0005-y","volume":"29","author":"T Zhang","year":"2012","unstructured":"Zhang T, Zhao C, Luo L, Zhao H, Cheng J, Xu F. The expression of Mcl-1 in human cervical cancer and its clinical significance. Med Oncol. 2012;29:1985\u201391.","journal-title":"Med Oncol"},{"key":"1679_CR45","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.3892\/ijo.2015.2890","volume":"46","author":"W-S Lee","year":"2015","unstructured":"Lee W-S, Park Y-L, Kim N, Oh H-H, Son D-J, Kim M-Y, et al. Myeloid cell leukemia-1 regulates the cell growth and predicts prognosis in gastric cancer. Int J Oncol. 2015;46:2154\u201362.","journal-title":"Int J Oncol"},{"key":"1679_CR46","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/bjc.1998.466","volume":"78","author":"RA Crawford","year":"1998","unstructured":"Crawford RA, Caldwell C, Iles RK, Lowe D, Shepherd JH, Chard T. Prognostic significance of the bcl-2 apoptotic family of proteins in primary and recurrent cervical cancer. Br J Cancer. 1998;78:210\u20134.","journal-title":"Br J Cancer."},{"key":"1679_CR47","doi-asserted-by":"publisher","first-page":"100756","DOI":"10.1016\/j.bbrep.2020.100756","volume":"22","author":"SFA Rahman","year":"2020","unstructured":"Rahman SFA, Muniandy K, Soo YK, Tiew EYH, Tan KX, Bates TE, et al. Co-inhibition of BCL-XL and MCL-1 with selective BCL-2 family inhibitors enhances cytotoxicity of cervical cancer cell lines. Biochem Biophysics Rep. 2020;22:100756.","journal-title":"Biochem Biophysics Rep."},{"key":"1679_CR48","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.cell.2011.08.037","volume":"147","author":"J Liu","year":"2011","unstructured":"Liu J, Xia H, Kim M, Xu L, Li Y, Zhang L, et al. Beclin1 controls the levels of p53 by regulating the deubiquitination activity of USP10 and USP13. Cell. 2011;147:223\u201334.","journal-title":"Cell."},{"key":"1679_CR49","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1186\/s13104-018-3302-0","volume":"11","author":"BSX Lian","year":"2018","unstructured":"Lian BSX, Yek AEH, Shuvas H, Rahman SFA, Muniandy K, Mohana-Kumaran N. Synergistic anti-proliferative effects of combination of ABT-263 and MCL-1 selective inhibitor A-1210477 on cervical cancer cell lines. BMC Res Notes 2018;11:197\u20137.","journal-title":"BMC Res Notes"},{"key":"1679_CR50","doi-asserted-by":"publisher","first-page":"279ra40","DOI":"10.1126\/scitranslmed.aaa4642","volume":"7","author":"JD Leverson","year":"2015","unstructured":"Leverson JD, Phillips DC, Mitten MJ, Boghaert ER, Diaz D, Tahir SK, et al. Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy. Sci Transl Med. 2015;7:279ra40\u2013279ra40.","journal-title":"Sci Transl Med"},{"key":"1679_CR51","first-page":"50","volume":"1855","author":"J Liu","year":"2015","unstructured":"Liu J, Shaik S, Dai X, Wu Q, Zhou X, Wang Z, et al. Targeting the ubiquitin pathway for cancer treatment. Biochimica et biophysica acta. 2015;1855:50\u201360.","journal-title":"Biochimica et biophysica acta."},{"key":"1679_CR52","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1182\/blood-2009-07-231191","volume":"115","author":"GW Xu","year":"2010","unstructured":"Xu GW, Ali M, Wood TE, Wong D, Maclean N, Wang X, et al. The ubiquitin-activating enzyme E1 as a therapeutic target for the treatment of leukemia and multiple myeloma. Blood. 2010;115:2251\u20139.","journal-title":"Blood."},{"key":"1679_CR53","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1111\/imm.12255","volume":"142","author":"C Chen","year":"2014","unstructured":"Chen C, Meng Y, Wang L, Wang H-X, Tian C, Pang G-D, et al. Ubiquitin-activating enzyme E1 inhibitor PYR41 attenuates angiotensin II-induced activation of dendritic cells via the I\u03baBa\/NF-\u03baB and MKP1\/ERK\/STAT1 pathways. Immunology. 2014;142:307\u201319.","journal-title":"Immunology."},{"key":"1679_CR54","doi-asserted-by":"publisher","first-page":"20265","DOI":"10.18632\/oncotarget.24750","volume":"9","author":"A McHugh","year":"2018","unstructured":"McHugh A, Fernandes K, South AP, Mellerio JE, Salas-Alan\u00eds JC, Proby CM, et al. Preclinical comparison of proteasome and ubiquitin E1 enzyme inhibitors in cutaneous squamous cell carcinoma: the identification of mechanisms of differential sensitivity. Oncotarget. 2018;9:20265\u201381.","journal-title":"Oncotarget."},{"key":"1679_CR55","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41375-018-0167-0","volume":"33","author":"SH Barghout","year":"2019","unstructured":"Barghout SH, Patel PS, Wang X, Xu GW, Kavanagh S, Halgas O, et al. Preclinical evaluation of the selective small-molecule UBA1 inhibitor, TAK-243, in acute myeloid leukemia. Leukemia. 2019;33:37\u201351.","journal-title":"Leukemia."},{"key":"1679_CR56","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1021\/acschembio.5b00222","volume":"10","author":"CD Hodge","year":"2015","unstructured":"Hodge CD, Edwards RA, Markin CJ, McDonald D, Pulvino M, Huen MSY, et al. Covalent Inhibition of Ubc13 Affects Ubiquitin Signaling and Reveals Active Site Elements Important for Targeting. ACS Chem Biol. 2015;10:1718\u201328.","journal-title":"ACS Chem Biol"},{"key":"1679_CR57","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jbior.2015.10.009","volume":"60","author":"AP Fields","year":"2016","unstructured":"Fields AP, Justilien V, Murray NR. The chromosome 3q26 OncCassette: A multigenic driver of human cancer. Adv Biol Regul. 2016;60:47\u201363.","journal-title":"Adv Biol Regul."},{"key":"1679_CR58","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1038\/onc.2016.330","volume":"36","author":"Y Wang","year":"2017","unstructured":"Wang Y, Ou Z, Sun Y, Yeh S, Wang X, Long J, et al. Androgen receptor promotes melanoma metastasis via altering the miRNA-539-3p\/USP13\/MITF\/AXL signals. Oncogene. 2017;36:1644\u201354.","journal-title":"Oncogene."},{"key":"1679_CR59","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1084\/jem.20151673","volume":"214","author":"X Fang","year":"2017","unstructured":"Fang X, Zhou W, Wu Q, Huang Z, Shi Y, Yang K, et al. Deubiquitinase USP13 maintains glioblastoma stem cells by antagonizing FBXL14-mediated Myc ubiquitination. J Exp Med. 2017;214:245\u201367.","journal-title":"J Exp Med."},{"key":"1679_CR60","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/nrd.2016.253","volume":"16","author":"A Ashkenazi","year":"2017","unstructured":"Ashkenazi A, Fairbrother WJ, Leverson JD, Souers AJ. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors. Nat Rev Drug Discov. 2017;16:273\u201384.","journal-title":"Nat Rev Drug Discov."},{"key":"1679_CR61","doi-asserted-by":"publisher","first-page":"8482","DOI":"10.1002\/jcp.26786","volume":"233","author":"AD Blasio","year":"2018","unstructured":"Blasio AD, Vento R, Fiore RD. Mcl-1 targeting could be an intriguing perspective to cure cancer. J Cell Physiol. 2018;233:8482\u201398.","journal-title":"J Cell Physiol."},{"key":"1679_CR62","doi-asserted-by":"crossref","unstructured":"Wei AH, Roberts AW, Spencer A, Rosenberg AS, Siegel D, Walter RB, et al. Targeting MCL-1 in hematologic malignancies: Rationale and progress. Blood Rev. 2020;44:100672.","DOI":"10.1016\/j.blre.2020.100672"},{"key":"1679_CR63","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/s41418-019-0486-3","volume":"27","author":"VV Senichkin","year":"2020","unstructured":"Senichkin VV, Streletskaia AY, Gorbunova AS, Zhivotovsky B, Kopeina GS. Saga of Mcl-1: regulation from transcription to degradation. Cell death Differ. 2020;27:405\u201319.","journal-title":"Cell death Differ."},{"key":"1679_CR64","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1186\/s12935-019-0936-5","volume":"19","author":"L Wu","year":"2019","unstructured":"Wu L, Lin Y, Feng J, Qi Y, Wang X, Lin Q, et al. The deubiquitinating enzyme OTUD1 antagonizes BH3-mimetic inhibitor induced cell death through regulating the stability of the MCL1 protein. Cancer Cell Int. 2019;19:222\u201311.","journal-title":"Cancer Cell Int."},{"key":"1679_CR65","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/s41418-019-0339-0","volume":"27","author":"X Wu","year":"2020","unstructured":"Wu X, Luo Q, Zhao P, Chang W, Wang Y, Shu T, et al. JOSD1 inhibits mitochondrial apoptotic signalling to drive acquired chemoresistance in gynaecological cancer by stabilizing MCL1. Cell Death Differ. 2020;27:55\u201370.","journal-title":"Cell Death Differ."},{"key":"1679_CR66","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/nature03579","volume":"435","author":"T Oltersdorf","year":"2005","unstructured":"Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature. 2005;435:677\u201381.","journal-title":"Nature."},{"key":"1679_CR67","doi-asserted-by":"publisher","first-page":"3421","DOI":"10.1158\/0008-5472.CAN-07-5836","volume":"68","author":"C Tse","year":"2008","unstructured":"Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, Jin S, et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 2008;68:3421\u20138.","journal-title":"Cancer Res."},{"key":"1679_CR68","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1513257","volume":"374","author":"AW Roberts","year":"2016","unstructured":"Roberts AW, Davids MS, Pagel JM, Kahl BS, Puvvada SD, Gerecitano JF, et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. New Engl J Med. 2016;374:311\u201322.","journal-title":"New Engl J Med"},{"key":"1679_CR69","doi-asserted-by":"publisher","first-page":"3069","DOI":"10.1158\/0008-5472.CAN-11-4106","volume":"72","author":"S Mazumder","year":"2012","unstructured":"Mazumder S, Choudhary GS, Al-Harbi S, Almasan A. Mcl-1 Phosphorylation defines ABT-737 resistance that can be overcome by increased NOXA expression in leukemic B cells. Cancer Res. 2012;72:3069\u201379.","journal-title":"Cancer Res."},{"key":"1679_CR70","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/1476-4598-13-98","volume":"13","author":"B Wang","year":"2014","unstructured":"Wang B, Ni Z, Dai X, Qin L, Li X, Xu L, et al. The Bcl-2\/xL inhibitor ABT-263 increases the stability of Mcl-1 mRNA and protein in hepatocellular carcinoma cells. Mol Cancer. 2014;13:98\u201311.","journal-title":"Mol Cancer."},{"key":"1679_CR71","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/s41419-020-2646-2","volume":"11","author":"N Mukherjee","year":"2020","unstructured":"Mukherjee N, Skees J, Todd KJ, West DA, Lambert KA, Robinson WA, et al. MCL1 inhibitors S63845\/MIK665 plus Navitoclax synergistically kill difficult-to-treat melanoma cells. Cell Death Dis. 2020;11:443\u201314.","journal-title":"Cell Death Dis."},{"key":"1679_CR72","doi-asserted-by":"publisher","first-page":"4225","DOI":"10.1158\/0008-5472.CAN-12-1118","volume":"72","author":"S Chen","year":"2012","unstructured":"Chen S, Dai Y, Pei X-Y, Myers J, Wang L, Kramer LB, et al. CDK inhibitors upregulate BH3-only proteins to sensitize human myeloma cells to BH3 mimetic therapies. Cancer Res. 2012;72:4225\u201337.","journal-title":"Cancer Res"},{"key":"1679_CR73","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.neo.2015.07.003","volume":"17.","author":"I Kiprianova","year":"2015","unstructured":"Kiprianova I, Remy J, Milosch N, Mohrenz IV, Seifert V, Aigner A. et al. Sorafenib sensitizes glioma cells to the BH3 mimetic ABT-737 by targeting MCL1 in a STAT3-dependent manner. Neoplasia (N. Y, NY). 2015;17.:564\u201373.","journal-title":"Neoplasia (N. Y, NY)"},{"key":"1679_CR74","doi-asserted-by":"publisher","first-page":"5802","DOI":"10.1200\/JCO.2008.16.4368","volume":"26","author":"Collaboration C for CCM-A.","year":"2008","unstructured":"Collaboration C for CCM-A. Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials. J Clin Oncol. 2008;26:5802\u201312.","journal-title":"J Clin Oncol."},{"key":"1679_CR75","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0096801","volume":"9","author":"F Varghese","year":"2014","unstructured":"Varghese F, Bukhari AB, Malhotra R, De A. IHC Profiler: an open source plugin for the quantitative evaluation and automated scoring of immunohistochemistry images of human tissue samples. PloS One 2014;9:e96801.","journal-title":"PloS One"},{"key":"1679_CR76","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1136\/jcp.48.9.876","volume":"48","author":"S Detre","year":"1995","unstructured":"Detre S, Jotti GS, Dowsett MA. \u201cQuickscore\u201d method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas. J Clin Pathol. 1995;48:876\u20138.","journal-title":"J Clin Pathol."},{"key":"1679_CR77","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1006975","volume":"14","author":"EL Morgan","year":"2018","unstructured":"Morgan EL, Wasson CW, Hanson L, Kealy D, Pentland I, McGuire V, et al. STAT3 activation by E6 is essential for the differentiation-dependent HPV18 life cycle. PLoS Pathog. 2018;14:e1006975.","journal-title":"PLoS Pathog."},{"key":"1679_CR78","doi-asserted-by":"publisher","first-page":"13853","DOI":"10.1128\/JVI.02159-13","volume":"87","author":"DA Griffiths","year":"2013","unstructured":"Griffiths DA, Abdul-Sada H, Knight LM, Jackson BR, Richards K, Prescott EL, et al. Merkel cell polyomavirus small T antigen targets the NEMO adaptor protein to disrupt inflammatory signaling. J Virol. 2013;87:13853\u201367.","journal-title":"J Virol"},{"issue":"Mar","key":"1679_CR79","first-page":"260","volume":"10","author":"D Das","year":"2019","unstructured":"Das D, Bristol ML, Smith NW, James CD, Wang X, Pichierri P, et al. Werner helicase control of human papillomavirus 16 E1-E2 DNA replication is regulated by SIRT1 deacetylation. mBio 2019;10(Mar):260.","journal-title":"mBio"},{"key":"1679_CR80","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.2005752","volume":"16","author":"I Pentland","year":"2018","unstructured":"Pentland I, Campos-Le\u00f3n K, Cotic M, Davies K-J, Wood CD, Groves IJ, et al. Disruption of CTCF-YY1-dependent looping of the human papillomavirus genome activates differentiation-induced viral oncogene transcription. PLoS Biol 2018;16:e2005752.","journal-title":"PLoS Biol"},{"key":"1679_CR81","doi-asserted-by":"publisher","first-page":"W488","DOI":"10.1093\/nar\/gkaa216","volume":"48","author":"A Ianevski","year":"2020","unstructured":"Ianevski A, Giri AK, Aittokallio T. SynergyFinder 2.0: visual analytics of multi-drug combination synergies. Nucleic Acids Res. 2020;48:W488\u201393.","journal-title":"Nucleic Acids Res."}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41388-021-01679-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41388-021-01679-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41388-021-01679-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T17:21:52Z","timestamp":1684603312000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-021-01679-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,24]]},"references-count":81,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,3,18]]}},"alternative-id":["1679"],"URL":"https:\/\/doi.org\/10.1038\/s41388-021-01679-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.07.25.220996","asserted-by":"object"}]},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,24]]},"assertion":[{"value":"25 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The author declares no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}